BRD4 has also been proven to be a necessary co-activator of the inflammatory transcription process driven by the combination of NF-κB with acetylated RelA, and a necessary co-activator of the diacetylated form of TWIST in triple negative breast cancer [33,34]. Here, NFKB1 is linked to triple-negative breast carcinoma.